EPCAM and hepatocellular carcinoma: In a study, the results showed that 30.5% (18/59) of HCC patients have EpCAM+ CTCs, while this marker was found in only 5.3% (1/19) of individuals in the control group of patients with cirrhosis or benign hepatic tumor (Table 4).